Published by:
Ousler G, et al. Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Read next
VIDEO: SkQ1 reduced corneal staining, improved vision in dry eye
Published by:
Ousler G, et al. Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Click Here to Manage Email Alerts
DENVER – Treatment with the mitochondrial reactive oxygen species scavenger Visomitin resulted in reduced corneal staining and improved visual function in patients with dry eye, according to a study presented here at ARVO.
George Ousler, Ora Inc. senior vice president of anterior segment, said that Mitotech’s SkQ1 ophthalmic solution is a “novel therapeutic approach to dry eye.”
Read more about
Click Here to Manage Email Alerts
